Myeloid growth factors (MGFs) are given as supportive care to patients receiving myelosuppressive chemotherapy to reduce the incidence of neutropenia. This selection from the NCCN Guidelines for MGFs focuses on the evaluation of regimenand patient-specific risk factors for the development of febrile neutropenia (FN), the prophylactic use of MGFs for the prevention of chemotherapy-induced FN, and assessing the risks and benefits of MGF use in clinical practice.
|Original language||English (US)|
|Number of pages||22|
|Journal||JNCCN Journal of the National Comprehensive Cancer Network|
|State||Published - Dec 1 2017|
ASJC Scopus subject areas